Vapotherm Inc.

107 Ridgely Avenue
Suite 9
Annapolis
Maryland
21401
United States

Tel: 410-974-9255
Fax: 410-974-9707

Email: INFO@VTHERM.COM

Show jobs for this employer

67 articles with Vapotherm Inc.

  • Vapotherm, Inc. announced the release of a low-cost, easy to use kit to help clinicians create a zone of relative negative pressure at the patient's face which may mitigate the risk of transmission of potentially infectious particles while treating COVID-19 patients.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 via webcast.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced second quarter 2020 financial results.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of Vapotherm’s proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2020 after the close of trading on Tuesday, August 4, 2020.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients suffering from respiratory distress, announced a major expansion in its capital equipment manufacturing capabilities.

  • Vapotherm, Inc. announced that its management team will be presenting at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020 via webcast.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be presenting at the Bank of America Securities Health Care Conference 2020 on Thursday, May 14, 2020 via webcast.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the commencement of a proposed public offering of $75 million of its shares of common stock.

  • Vapotherm, Inc.,, a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced first quarter 2020 financial results.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Tuesday, May 5, 2020.

  • April 13, 2020 11:00 UTC Preliminary first quarter revenue of approximately $18.9 million represents 54% increase as compared to the first quarter of 2019

  • Vapotherm, Inc. announced that the U.S. Food and Drug Administration recently granted Breakthrough Device Designation for the Company’s Oxygen Assist Module.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.

  • Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2019 financial results.

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the fourth quarter and fiscal year 2019 after the close of trading on Wednesday, March 4, 2020

  • Vapotherm, Inc. (NYSE: VAPO) today announced that it has received the CE Mark for its Vapotherm Oxygen Assist Module (OAM)

  • Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Lance Berry to its Board of Directors, and as a member and chair of the Audit Committee, both effective on January 29, 2020

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced certain preliminary unaudited fourth quarter and full year 2019 revenue results.

  • Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced its financial and operating results for the third quarter ended September 30, 2019.